Digitally enhances adult and pediatric radiographic x-ray images; mammography is excluded.
Clinical role
Image processing within the ImageView application software: an optional CNN-based noise cancellation module suppresses noise before enhancement of CR and DR radiographs, presenting images with proper quality attributes to help radiologists and physicians make a diagnosis.
Images and patients
X-ray/Radiography
Key limitation
Non-standalone ImageView module for CR/DR projection radiography; mammography is excluded; additional exact limits are unknown.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyX-ray/Radiography
Workflow roleImage processing within the ImageView application software: an optional CNN-based noise cancellation module suppresses noise before enhancement of CR and DR radiographs, presenting images with proper quality attributes to help radiologists and physicians make a diagnosis.
Required inputProjection-radiography acquisitions from computed-radiography or digital-radiography receptors.
Output and human actionA digitally enhanced radiographic image, with noise suppression before enhancement and an estimated-noise 2D Noise Field used in processing.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Digitally enhances adult and pediatric radiographic x-ray images; mammography is excluded.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Image processing within the ImageView application software: an optional CNN-based noise cancellation module suppresses noise before enhancement of CR and DR radiographs, presenting images with proper quality attributes to help radiologists and physicians make a diagnosis.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Eclipse software runs inside the ImageView product application software (not considered stand-alone software). Smart Noise Cancellation is an optional feature (module) that enhances projection radiography acquisitions captured from digital radiography imaging receptors (Computed Radiography (CR) and Digital Radiography (DR)." … "The difference in the modified software is the implementation of noise suppression prior to enhancement processing. The Smart Noise Cancellation operation passes the acquired preprocessed image through a specially trained Convolutional Neural Network (CNN)". Read from the exact FDA decision document on 2026-11-14.
FDA summary reports no additional non-clinical testing and a concurrence study using visual-difference and RadLex scales; it reports 50% CsI and 40% GOS dose-reduction testing, with sample size and sites unknown.
Exact FDA submission
Checked 2026-09-19
Submission-reported testing only; not independent validation.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA summary reports no additional non-clinical testing and a concurrence study using visual-difference and RadLex scales; it reports 50% CsI and 40% GOS dose-reduction testing, with sample size and sites unknown.
FDA source
Exact FDA submission
Checked 2026-09-19
Submission-reported testing only; not independent validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Eclipse II with Smart Noise Cancellation regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult and Pediatric
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K213307
IndependenceIndependence not established
K213307
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K213307. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Projection-radiography acquisitions from computed-radiography or digital-radiography receptors.
Scope: Exact FDA submission. FDA device description and technological-characteristics scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-11-14 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-09 ·
Returned objects
Source context, not route validation: A digitally enhanced radiographic image, with noise suppression before enhancement and an estimated-noise 2D Noise Field used in processing.
Scope: Exact FDA submission. FDA device description.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: A digitally enhanced radiographic image, with noise suppression before enhancement and an estimated-noise 2D Noise Field used in processing.
Scope: Exact FDA submission. FDA device description.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Carestream Health's cybersecurity and privacy page describes a product security program: coordinated vulnerability disclosure, MDS2 statements, published product security advisories with patch information, security configuration documentation for product operating systems, and a customer service portal providing security advisories, updates, network maps, SBOM, firewall and group-policy configuration.
Vendor-wide
Checked 2026-10-27
Vendor statement; portal content is customer-gated. Applied only to Carestream Health, Inc. entries; CARESTREAM DENTAL LLC is a separate company and was not bridged. Exact-release scope is not established.
Carestream Health's cybersecurity and privacy page states a coordinated vulnerability disclosure process, product security advisories with patch information, OS security configuration documentation, and a customer portal carrying advisories, updates, network maps, SBOM and firewall/group-policy configuration.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Carestream Health generally and does not scope these commitments to any specific product release; exact-release scope is not established. The customer portal is customer-gated; its contents were not read.
ACR AI Central provides an exact-submission model card for Eclipse II with Smart Noise Cancellation; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
23Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA decision-summary packet reviewed on 2026-09-19. Applied FDA-supported reader facts: purpose, modality, intendedUsers, input, output, limitations, evidenceSummary. Facts marked unknown in the FDA packet retain any prior non-FDA source without reclassification. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K213307 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-09 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Integration: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: uDR Aurora CX acquires two-dimensional X-ray images of the labeled skull, spine, chest, abdomen, extremities, limbs, and trunk for review by qualified healthcare professionals; it is not a mammography system.
Modality
X-ray/Radiography
Anatomy
Skull, spine, chest, abdomen, extremities, limbs, and trunk
Authorized purpose: Eclipse II with Smart Noise Cancellation digitally enhances radiographic images generated by supported X-ray devices for adult and pediatric use; the cleared function is for projection radiography and excludes mammography.
Modality
X-ray/Radiography
Anatomy
Adult and pediatric radiographic anatomy excluding mammography
Authorized purpose: YSIO MAX is a digital radiography system for whole-body skull, chest, abdomen, and extremity imaging in pediatric, adult, and bariatric patients, including supported emergency and small-intervention positions; it is not a mammography system.
Authorized purpose: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.